All In Biotech

Drug Trial Radar · NCT07367724

Ademetionine in Obstructive Hypertrophic Cardiomyopathy

Safety and Efficacy of Ademetionine in Patients With Obstructive Hypertrophic Cardiomyopathy: A Multicenter, Double-Blind, Randomized Controlled, Phase 2 Study

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
China National Center for Cardiovascular DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

  • Ademetionine 1,4-ButanedisulfonateDrug

    Ademetionine 1,4-Butanedisulfonate is the currently available marketed oral pharmaceutical formulation of S-adenosylmethionine. Its brand name is Ximeixin in China.

  • PlaceboDrug

    The placebo is a starch tablet identical in appearance, odor, and other physical properties.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pVO₂ by CPET from baseline to Week 16Time frame: From enrollment to the end of treatment at 16 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, China · Recruiting

  • Zhongshan Hospital, Shanghai Medical College of Fudan University

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Xinjiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.